The somatostatin analog octreotide as potential treatment for re-stenosis and chronic rejection.
Weckbecker
G
G
Transplantation and Core Technology Department, Novartis Pharma Research, Basel, Switzerland.
Pally
C
C
Raulf
F
F
Beckmann
N
N
Schuurman
J H
JH
Rudin
M
M
Bruns
C
C
D017130:Angioplasty / Q000009:adverse effects; D000818:Animals; D001807:Blood Vessel Prosthesis / Q000009:adverse effects; D002339:Carotid Arteries / Q000473:pathology; D002455:Cell Division / Q000187:drug effects; D002465:Cell Movement / Q000187:drug effects; D006083:Graft Occlusion, Vascular / Q000517:prevention & control*; D006728:Hormones / Q000008:administration & dosage*; D015282:Octreotide / Q000008:administration & dosage*; D051381:Rats; D017540:Tunica Media / Q000187:drug effects / Q000473:pathology*; D014652:Vascular Diseases / Q000188:drug therapy* / Q000473:pathology
D006728:Hormones; D015282:Octreotide